熱景生物(688068.SH):公司產品銷售存在激烈市場競爭的風險
格隆匯1月12日丨熱景生物(688068.SH)發佈股票交易異常波動公吿,公司股價連續上漲積累的獲利調整風險。自2022年1月5日起,公司已兩次觸及3個交易日內收盤價格漲幅偏離值累計達到30%的股價異常波動公吿規則,股價連續上漲積累了較多的獲利調整風險。公司特別提醒廣大投資者注意投資風險,避免跟風炒作,理性決策,審慎投資。
公司相關新冠檢測產品獲得歐盟CE等主要經濟體註冊/備案非獨家專屬風險。公司新冠抗原檢測試劑所獲得的歐盟CE等主要經濟體註冊/備案非公司獨家專屬,市場同類或類似競爭產品較多,公司產品銷售存在激烈市場競爭的風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.